M33 Growth I L.P. Reduces Stake in Oncology Institute, Inc. Below 5% Threshold

M33 Growth I L.P., along with M33 Growth I GP LLC and TOI M, LLC, filed an Amendment No. 6 to their Schedule 13D for Oncology Institute, Inc. (TOI) on May 15, 2026. The filing reports that between May 8, 2026, and May 14, 2026, M33 Growth I L.P. sold an aggregate of 1,800,000 shares of Common Stock in open market transactions on Nasdaq. Following these sales, the Reporting Persons' combined beneficial ownership decreased to 5,002,656 shares, which represents approximately 4.94% of the company's outstanding common stock. This total includes 3,644,207 shares of Common Stock and 1,358,449 shares issuable upon the exercise of warrants. Because their ownership stake has fallen below the 5% threshold, the Reporting Persons have ceased to be beneficial owners of more than five percent of the issuer's Common Stock. The sales occurred at prices ranging from approximately $4.01 to $4.14 per share. TOI M, LLC reported zero holdings following a previous distribution of shares.